On September 16, Green Valley and Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences (CAS) signed a strategic cooperation agreement in Shanghai to promote the industry application of the “Ultrasonic Radiation Force-Based Deep Brain Stimulation and Neuromodulation Technology” developed under the "National Programme of Developing Key Scientific Research Instruments." The agreement is aimed at contributing to this pioneering and global leading core technology for its entering into the fast lane of industry application.

More than 20 representatives from both parties, including academician Ding Jian, director of Green Valley Research Institute, Geng Meiyu, a researcher at the Shanghai Institute of Materia Medica of Chinese Academy of Sciences and the principal inventor of GV-971, Professor Zhang Zhenqing, associate director of the Green Valley Research Institute, Zheng Hairong, associate director of the Shenzhen Institute of Advanced Technology, Liu Xin, deputy head of the Institute of Biomedical and Health Engineering at the Shenzhen Institute of Advanced Technology, and Xia Hongliu, deputy director of the Business Management Office at the Shenzhen Institute of Advanced Technology attended the signing ceremony.

According to the agreement, Green Valley will establish a joint venture (Zhongke Green Valley Medical Equipment Co., Ltd.) with the Shenzhen Institute of Advanced Technology to leverage the leading position of the Shenzhen Institute of Advanced Technology in ultrasonic technology and the core competitiveness of Green Valley in the research, diagnosis, and treatment of brain diseases. This joint venture will result in the co-building of a technologically advanced and indigenous non-drug treatment platform for brain diseases in China. This platform will promote further application of global leading ultrasonic diagnosis and treatment technology in the healthcare industry.

The project of developing “Ultrasonic Radiation Force-Based Deep Brain Stimulation and Neuromodulation instruments” falls under the "National Development Programme of Key Scientific Research Instruments." It was approved by the National Natural Science Foundation of China and run by the Shenzhen Institute of Advanced Technology. The project will provide innovative tools and methods for brain research and the treatment of brain diseases including Alzheimer's disease, Parkinson's disease, and depression. These methods and treatments will eventually be applied in clinical practices.

Under this project, the Shenzhen Institute of Advanced Technology developed the world's first ultrasonic brain modulation methods and verification system based on the new principle that ultrasonic waves can modulate the electrical activities of nerve cells under specific acoustic conditions. Consisting of a range of core components including an ultrasonic radiation force generator based on a large-scale area array, the new instrument system can exert non-invasive and precise stimulation and modulations on nerves in deep brain tissues and throughout the entire depth of the brain down to the millimeter level. It has great value in science and medicine and is expected to benefit hundreds of millions of patients with brain and neuropsychiatric diseases worldwide.

The Green Valley Pharmaceutical Co., Ltd. is an innovative pharmaceutical company at the forefront of China's biopharmaceutical industry. It conducts research covering neuropsychiatric diseases, cardiovascular diseases, tumor, metabolic diseases, and other complex chronic diseases. The company is building on the success of its GV-971, a Chinese innovator drug against Alzheimer's disease, to further explore the diagnosis and treatment of brain diseases. Furthermore, Green Valley is constructing a precise diagnosis and treatment platform for those same brain diseases combining drug treatments and non-drug treatments.

Fan Jianping, director of the Shenzhen Institute of Advanced Technology, is optimistic and confident about the strategic cooperation. He said at the signing ceremony, "Probing the mysteries of the brain and modulating its neuronal activities are the ultimate challenges in global biomedical research and the prerequisites for effective intervention and treatment of brain dysfunctions including Parkinson's disease, dementia, and depression. Zheng Hairong, a researcher at the Shenzhen Institute of Advanced Technology, and his team at the Paul C. Lauterbur Research Center for Biomedical Imaging were the first to propose new methods of neuromodulation in the international research arena. This query has arouse wide international attention and enabled his research team to lead the research of ultrasonic neuromodulation. By establishing a strategic partnership with Green Valley, we hope to draw on Green Valley's strong marketing team and R&D advantages in drug development for neuropsychiatric diseases and research of brain disease pathogeneses. These efforts will accelerate the industry application of technologies developed under the National Programme of Developing Key Scientific Research Instruments and benefit more patients."

Lv Songtao, president of Green Valley, said, "Green Valley has a long history of cooperating with the Chinese Academy of Sciences. We established long-term strategic partnership with the Shanghai Institute of Materia Medica of Chinese Academy of Sciences, and co-developed carbohydrate drug development technologies unique to Green Valley. We believe that by partnering with the Shenzhen Institute of Advanced Technology, Green Valley will further improve its R&D capacity in brain disease diagnosis and treatment. This is an important move by Green Valley to promote the development of research on brain disease pathogeneses as well as their diagnoses and treatment. It marks another important step forward in Green Valley's efforts to develop the blueprint for future development of the brain health industry. Since Green Valley's foundation, the company has always adhered to innovation and refused to follow and copy others. The successful completion of phase III clinical trial for GV-971 this year is the best proof of Green Valley's dedication to originality and innovation. We believe that in the future, ultrasonic technology for brain disease treatment will become the next breakthrough innovator technology that will benefit patients around the world. Green Valley will work with partners from across multiple sectors with an open attitude, just as they always have. Green Valley will combine drug treatment with breakthroughs in non-drug treatment and build a platform for the precise diagnosis and treatment of brain diseases, so as to benefit patients across the globe.”